Allos Therapeutics Announces Pricing of Common Stock Offering
31 Mars 2009 - 3:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ:ALTH) announced today the
pricing of an underwritten public offering of 7,750,000 shares of
its common stock. The Company expects the offering to close on or
about April 3, 2009, subject to customary closing conditions.
UBS Investment Bank is the sole manager for the offering. The
Company has granted the underwriter a 30-day option to purchase up
to an additional 1,162,500 shares to cover over-allotments, if any.
The Company plans to use the net proceeds from the offering
primarily for activities relating to preparations for the potential
commercial launch of pralatrexate, clinical and preclinical
research and development of pralatrexate, working capital and
general corporate purposes.
A registration statement relating to these shares was filed with
the Securities and Exchange Commission and declared effective on
June 5, 2007. This offering is being made pursuant to a prospectus
supplement to the registration statement. Copies of the prospectus
supplement relating to this offering, when available, may be
obtained from UBS Investment Bank, Attention: Prospectus
Department, 299 Park Avenue, New York, NY 10171, or by calling
(888) 827-7275.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy the Company's common
stock, nor shall there be any sale of the common stock in any state
or jurisdiction in which such an offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any state.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on
developing and commercializing innovative small molecule drugs for
the treatment of cancer.
Safe Harbor Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements concerning the completion of the
offering, the amount of the net proceeds, the potential to complete
the Company�s ongoing development programs with the proceeds of the
financing, and other statements which are other than statements of
historical facts. In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should,"
"expects," "intends," "plans," anticipates," "believes,"
"estimates," "predicts," "projects," "potential," "continue," and
other similar terminology or the negative of these terms, but their
absence does not mean that a particular statement is not
forward-looking. Such forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties
that may cause actual results to differ materially from those
anticipated by the forward-looking statements. These risks and
uncertainties include, among others: the risk that the financing
may be delayed or may not occur due to market or other conditions
and the risk that additional capital may be required in the future
to complete on-going trials. Additional information concerning
these and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2008, the
Company's other periodic reports and filings with the SEC and the
prospectus supplement related to the offering. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this
presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024